GlassScriptPhysician profile
Joanna May
NPI 1588003495
$4,638.12
in general payments reported to CMS, 2019-2025
26 companies · $1,875 in 2025
The $1,875 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.23 · 2022: $704 · 2023: $568 · 2024: $1,425 · 2025: $1,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,868.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,305.01 | 2022-2025 | |
| Janssen Biotech, INC. | $499.26 | 2023-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.46 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $307.10 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $272.65 | 2023-2025 | |
| Ardelyx, INC. | $269.37 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $229.78 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $205.88 | 2022-2024 | Dupixent |
| Lilly USA, LLC | $201.99 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $187.50 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $130.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $124.97 | 2022 | |
| Novo Nordisk INC | $113.40 | 2023 | |
| Qol Medical, LLC | $100.45 | 2024-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $69.68 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $57.63 | 2023-2024 | Zeposia |
| Digestive Care, INC. | $41.59 | 2024 | Pertzye |
| Intercept Pharmaceuticals, INC. | $37.76 | 2024 | |
| Phathom Pharmaceuticals, INC. | $35.93 | 2025 | Voquezna |
| Enterra Medical, INC. | $31.59 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.07 | 2024 | Cyltezo |
| Aimmune Therapeutics, INC. | $19.47 | 2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $18.34 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.15 | 2024 | Givlaari |
| Teva Pharmaceuticals USA, INC. | $15.74 | 2024 | |
| Vivus LLC | $13.97 | 2024 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.